• Press Release

Scientists Led by Mount Sinai and Sema4 Identify Biomarker for Progression and Drug Response in Brain Cancer

Accurately subtyping glioblastoma tumors could lead to diagnostics and precision therapy

  • New York, NY
  • (October 16, 2017)

Scientists at the Icahn School of Medicine at Mount Sinai, Sema4, and collaborating institutions including Colorado State University and Fred Hutchinson Cancer Center reported results today from a glioblastoma study in which they validated a biomarker indicative of a patient’s prognosis and likely response to specific therapies. The article appeared in the October 15 issue of Cancer Research.

Glioblastoma is a highly aggressive and heterogeneous form of brain cancer, with a median survival time from diagnosis of just one year. Previous efforts to classify glioblastoma tumors into molecular subtypes for precision treatment have been largely unsuccessful. In this study, scientists developed an innovative computational method to classify tumors based on their dependency on a molecule, known as BUB1B, that some glioblastomas need to survive. The project revealed new tumor subtypes and found that BUB1B-sensitive tumors had significantly worse prognosis but were more likely to respond to many drugs already in clinical use.

“It was truly remarkable to see our predictive model yield a new set of molecular subtypes, which appear to be far more indicative of prognosis and therapeutic response than existing subtypes,” said Jun Zhu, PhD, Head of Data Sciences at Sema4, Professor of Genetics and Genomic Sciences at Mount Sinai, and senior author of the paper. “For patients who receive the grim diagnosis of glioblastoma, this signals new hope for tailored treatment more likely to be effective against their cancer.”

“This research is an outstanding example of how theoreticians working with complex datasets, and clinicians on the frontlines of patient care, can collaborate to uncover new insights into cancer biology that will directly impact clinical decision-making,” said Raymund Yong, MD, Assistant Professor of Neurosurgery and Assistant Professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, who made a significant contribution to tumor samples, glioma stem cells, and in vitro experiments in the paper.

Eric Schadt, PhD, Sema4 CEO and Dean for Precision Medicine at Mount Sinai, added: “These findings underscore the significant potential we see to improve patient outcomes by investing in predictive modeling of even the most complex types of cancer. We look forward to building on this collaborative project and moving toward development of a diagnostic test that could help physicians better understand and treat their patients’ glioblastoma cases.”

Paper cited: Lee E et al. Sensitivity to BUB1B inhibition defines an alternative classification of glioblastoma. Cancer Research, doi: 10.1158/0008-5472.CAN-17-0736

About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care. It is the medical school for the Mount Sinai Health System, an integrated health care system which includes seven hospitals and an expanding ambulatory network serving approximately 4 million patients per year.

The School has more than 1,800 students in MD, PhD, and Master’s programs and post-doctoral fellowships; more than 5,600 faculty members; over 2,000 residents and fellows; and 23 clinical and research institutes and 34 academic departments. It is ranked among the highest in the nation in National Institutes of Health funding per principal investigator. The School was the first medical school in the country to create a progressive admissions approach for students who seek early assurance of admission through the FlexMed program. For more information, visit http://icahn.mssm.edu or find the Icahn School of Medicine at Mount Sinai on FacebookTwitterYouTube, and LinkedIn

About Sema4
Sema4 is a next-generation health information company, spun out of the Mount Sinai Health System, that provides advanced genomic testing and merges big data analytics with clinical diagnostics.  Our team creates practical tools that help patients, clinicians, and researchers better diagnose, treat, and prevent disease. We are striving to construct a more comprehensive picture of health by integrating three key elements: a wealth of clinical experience that informs the answers that patients and providers are seeking, the world-class academic research that illuminates new directions, and the pioneering information science that puts all the pieces together. 

For more information, please visit sema4genomics.com and connect with Sema4 on FacebookTwitter, and YouTube.

# # #


About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.